ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

baricitinib

Also written as “Baricitinib”, “LY3009104” and “INCB028050”.

Its studies are mostly in Arthritis, Rheumatoid · Dermatitis, Atopic · Lupus Erythematosus, Systemic · COVID-19 · Arthritis, Juvenile, led by 5 companies.

Drug pageBaricitinib: every studyMany companies study it; this page follows only the 58 they lead. All 149 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 12, 201958 company-led studies, 7 open or runningNext primary completion: Jul 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only546 open or runningphase 4since Apr 12, 2019Aug 18, 2010Mar 2028phase 3 · NCT05723198
Galvani Bioelectronicsits history only11 open or runningno phasesince Jul 5, 2021Jul 5, 2021Jul 2027NCT05003310
Genuine Research Center, Egyptits history only10 open or runningphase 1since Aug 9, 2021Aug 9, 2021none ahead
Incepta Pharmaceuticalsits history only10 open or runningphase 3since Sep 20, 2021Sep 20, 2021none ahead
Incyte10 open or runningphase 2since May 13, 2009May 13, 2009none ahead

Also a collaborator on its studies: Q2 Solutions and Horus Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 13, 2009First study: phase 2 study in Arthritis, RheumatoidFirst studyNCT00902486 · 127 enrolled · United States, Czechia

TargetBeta

JAK1 →JAK2 →read by rule
“An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 331
delgocitinibruleLEO Pharmaphase 321
momelotinibruleGlaxoSmithKlinephase 317

Studies

The one study Incyte leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00902486Arthritis, Rheumatoid · United States, Czechia2CompletedJun 2010127

How it is read

Names in the registry

  • “Baricitinib”, 53 entries
  • “LY3009104”, 5 entries
  • “INCB028050”, 3 entries
  • “Barcimiant”, 1 entry
  • “Baricitinib suspension”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.